Category: Opinion

New Hope for Cancer Patients with No Other Treatment Options

Today we are pleased to announce Foresite Capital’s investment in ImmPACT Bio, which we co-led with Venbio and Decheng Capital. We’re excited about ImmPACT’s focus on next generation cancer therapies based on transformative chimeric antigen receptor (CAR) T-cell therapies for…

Read More

Announcing Fund V

Today is an important day in the history of Foresite Capital, the firm I founded in 2011: we announced our largest fundraise to date, $969 million in Fund V and its accompanying Opportunity Fund. We…

Read More

Reflecting on Kinnate Biopharma

Today is an important day for Foresite Capital and our portfolio company, Kinnate Biopharma. Kinnate began trading today on the NASDAQ (KNTE). I’d like to take a moment to reflect on the incredibly fast journey…

Read More